Apollomics Inc. received a Nasdaq notice for failing to maintain the minimum market value of $35 million, with a 180-day period to regain compliance by December 15, 2026. Separately, Apollomics terminated its agreement with Launxp International due to unpaid fees, regaining full rights to its cancer drug vebreltinib (APL-101) in Asia outside Mainland China and Macau. This consolidation allows Apollomics full strategic control over the drug's development and commercialization in the U.S., Europe, and Asia-Pacific, enhancing future partnership opportunities.
Snail Games announced the upcoming release of PixARK: Terracrypt, the first paid DLC for PixARK, offering over 200 hours of gameplay and 80 new creatures. The company is also participating in the 2026 Steam Summer Sale with significant discounts on P...
Fortuna Mining Corp. held its 2026 annual general meeting with 66.81% shareholder turnout. All business matters were approved, including the appointment of auditors, election of all nominated directors, and approval of the company's Share Unit Plan. ...
The QAIAx AI City Hall Project has launched the world's first federally registered clinical trial involving AI-governed smart microcities. These dome-enclosed communities integrate humanoid robots and quantum AI to manage public administration and pr...
SCOR announced that an arbitration tribunal confirmed the validity of reinsurance treaties made with Covéa in June 2021, involving the transfer of 30% of SCOR's Life & Health portfolio. The tribunal ruled in favor of Covéa, awarding $488.3 million in...
SCOR announced that an arbitration tribunal upheld the validity of retrocession treaties made with Covéa in June 2021, involving the transfer of 30% of SCOR's Life & Health portfolio in Ireland. The tribunal awarded Covéa compensation of USD 488.3 mi...
